AUS
NZ
UK
CA
USA
IND
Highlights
- The company has secured funding of up to $38.5 million from Clendon Biotech Capital.
- Funding to support IRX-211 (for breakthrough cancer pain) and IRX-616a (for panic disorder).
- Shares surged 36% following the announcement, reflecting strong investor optimism.
InhaleRx Ltd (ASX:IRX) saw a substantial 36% increase in its share price, trading at 3 cents per share following the announcement of a key funding agreement with Clendon Biotech Capital Pty Ltd. This strategic partnership will provide critical financial support to advance InhaleRx’s clinical development projects for IRX-211 and IRX-616a, both of which target unmet medical needs in pain management and mental health.
Key Highlights of the Announcement:
- Funding Secured: InhaleRx has obtained a funding facility of up to $38.5 million from Clendon Biotech Capital, covering all direct costs associated with the Phase 1 and 2 clinical trials for the IRX-211 and IRX-616a programs, including drug manufacturing and non-clinical work.
- Clinical Advancements: This funding will allow InhaleRx to progress clinical development, including addressing FDA requirements, ensuring the company remains on track to reach pivotal Phase 3 trials for both drugs in the next 2-3 years.
- Transformational Therapies:
- IRX-211 is a drug-device combination for Breakthrough Cancer Pain (BTcP), designed to provide rapid pain relief to cancer patients who experience sudden, intense episodes of pain despite chronic pain control.
- IRX-616a is an inhaled CBD-based therapy aimed at providing quick and effective relief for individuals suffering from Panic Disorder (PD), a condition marked by sudden and overwhelming episodes of anxiety.
Impact of Funding
The Clendon Biotech Capital funding will ensure that both projects can move forward without delay. This includes the activation of manufacturing and clinical trial phases for IRX-616a and IRX-211, positioning the company to meet FDA requirements and progress both drugs through to later-stage trials. The funding allows for drawdowns as eligible expenses are incurred, giving the company flexibility to execute its development strategy efficiently.
Strategic Importance of the Partnership
The agreement with Clendon Biotech Capital, a venture capital firm with a focus on bio-technology, marks a significant milestone for InhaleRx. It secures the company's ability to advance its inhaled therapeutic solutions, particularly in areas with high unmet clinical needs, including pain management and mental health.
Future Outlook
InhaleRx expects to accelerate its development timelines for IRX-211 and IRX-616a and capitalize on the growing demand for innovative inhaled therapies. The company remains confident in its ability to secure additional funding for operational and corporate overheads, ensuring continued sustainability as it moves towards Phase 3 clinical trials.
